# A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates

> **NCT07520760** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 52 (estimated)

## Conditions studied

- HER 2 Negative Breast Cancer

## Interventions

- **DRUG:** Eribulin in Combination with Anlotinib

## Key facts

- **NCT ID:** NCT07520760
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2030-04-30
- **Final completion:** 2035-04-30
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07520760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07520760, "A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07520760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*